22:47 , Apr 12, 2019 |  BioCentury  |  Finance

AskBio answers investors' call

Since 2001, gene therapy company Asklepios has subsisted chiefly on cash from licensing deals or transaction fees on programs sold off to biopharmas. Now, with $225 million in new series A funding from TPG Capital...
14:00 , Apr 11, 2019 |  BC Extra  |  Financial News

TPG, Vida back Asklepios in $235M round

TPG Capital and Vida Ventures have again teamed up to invest in a biotech's megaround, pouring a combined $225 million into gene therapy company Asklepios in exchange for a undisclosed minority stake. The company's founders...
22:33 , Jun 21, 2017 |  BC Extra  |  Company News

Sarepta gets option for Genethon's DMD gene therapy

Sarepta Therapeutics Inc. (NASDAQ:SRPT) said it gained an option to obtain exclusive U.S. rights from non-profit organization Genethon (Evry, France) to a gene therapy to treat Duchenne muscular dystrophy. The collaboration covers a Genethon preclinical...
07:00 , Aug 8, 2016 |  BC Week In Review  |  Company News

Bamboo, Pfizer deal

Pfizer acquired the 78% of Bamboo it did not already own for $150 million up front and up to $495 million in development, regulatory and commercialization milestones. In 1Q16, the pharma obtained a 22% stake...
07:00 , Aug 1, 2016 |  BC Extra  |  Company News

Pfizer acquires gene therapy company Bamboo

Pfizer Inc. (NYSE:PFE) acquired the 78% of Bamboo Therapeutics Inc. (Chapel Hill, N.C.) it did not already own for $150 million up front and $495 million in milestones. In 1Q16, the pharma obtained a 22%...
07:00 , Jul 18, 2016 |  BioCentury  |  Emerging Company Profile

Harnessing AAV tropisms

Bamboo Therapeutics Inc. is developing adeno-associated viral vector-based gene therapies that preferentially target tissues affected by CNS and neuromuscular disorders. By homing in on specific tissues, Bamboo's gene therapies could minimize off-target toxicities and reduce...
08:00 , Feb 1, 2016 |  BC Week In Review  |  Company News

Asklepios, Calimmune deal

Asklepios granted Calimmune rights to Asklepios’ adeno-associated virus (AAV) gene therapy technologies, which Calimmune plans to use in a Phase I/II trial of a gene therapy to treat osteoarthritis. Asklepios will receive an upfront payment...
07:00 , May 25, 2015 |  BC Week In Review  |  Company News

Asklepios, Benitec deal

Asklepios granted Benitec rights to advanced recombinant adeno-associated virus (AAV) gene therapy technologies. Benitec has access to the technologies for its Phase I/II trial of TT-034 to treat HCV infection. TT-034 is a DNA-directed RNAi...
07:00 , Apr 7, 2014 |  BC Week In Review  |  Company News

Asklepios, Baxter deal

Baxter will acquire Asklepios' Chatham Therapeutics LLC affiliate for $70 million up front. Chatham will also be eligible for undisclosed development, regulatory and sales milestones. Baxter declined to provide details. In May 2012, Chatham granted...
07:00 , Aug 6, 2012 |  BioCentury  |  Emerging Company Profile

Milo: Dismissing dystrophin

Milo Biotechnology LLC is developing a gene therapy to treat muscular dystrophy that up-regulates follistatin, a protein already present in the body, which could avoid immune reactions that have scuttled previous gene therapies. The company's...